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Abstract
Background: Dicer is an RNase III enzyme that cleaves double stranded RNA and generates functional interfering
RNAs that act as important regulators of gene and protein expression. Dicer plays an essential role during mouse
development because the deletion of the dicer gene leads to embryonic death. In addition, dicer-dependent
interfering RNAs regulate postnatal angiogenesis. However, the role of dicer is not yet fully elucidated during
vascular development.
Methods: In order to explore the functional roles of the RNA interference in vascular biology, we developed a new
constitutive Cre/loxP-mediated inactivation of dicer in tie2 expressing cells.
Results: We show that cell-specific inactivation of dicer in Tie2 expressing cells does not perturb early blood vessel
development and patterning. Tie2-Cre; dicerfl/fl mutant embryos do not show any blood vascular defects until
embryonic day (E)12.5, a time at which hemorrhages and edema appear. Then, midgestational lethality occurs at
E14.5 in mutant embryos. The developing lymphatic vessels of dicer-mutant embryos are filled with circulating red
blood cells, revealing an impaired separation of blood and lymphatic vasculature.
Conclusion: Thus, these results show that RNA interference perturbs neither vasculogenesis and developmental
angiogenesis, nor lymphatic specification from venous endothelial cells but actually provides evidence for an
epigenetic control of separation of blood and lymphatic vasculature.
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Background
RNA interference (RNAi) is a gene silencing pathway by
which specific messenger RNAs (mRNAs) are either de-
graded or translationally suppressed [1]. It is mediated
by microRNA (miRNA) or short interfering RNA (siRNA),
both non coding RNAs of 2022 nucleotides which are
matured by the RNase Dicer and are involved in base
pairing with target mRNAs. In mice, dicer is critical for
early mouse development because its abrogation prevents
the production of functional interfering RNAs resulting in
embryonic lethality at E7.5 [2]. A second study reported
death at E13.5 which was associated with angiogenesis
defects [3] but both studies were unable to decipher the
role of Dicer in specific vascular cell types. Conditional
ablation of dicer developed to investigate its function in
limb buds [4], in immune cells [5], and heart development
[6] have suggested important roles of RNA interference in
various biologic processes such as cell survival, prolifera-
tion, differentiation, and maintenance of cell function.
In angiogenesis, the role of Dicer-regulated miRNAs
was further suggested in mice expressing a hypomorphic
Dicer1 allele, which resulted in female infertility caused
by corpus luteum insufficiency and defective ovarian
angiogenesis [7]. In addition, Dicer has been shown
to have multiple roles in vascular biology. Tamoxifen-
inducible and smooth muscle cell (SMC)-specific dele-
tion of Dicer achieved by Cre-Lox recombination
showed that miRNAs are necessary for vascular smooth
muscle growth, differentiation, and function [8,9]. Dicer-
deficient mice exhibited a dramatic reduction in blood
pressure due to significant loss of vascular contractile
function and SMC contractile differentiation as well as
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vascular remodeling. This phenotype pointed to miRNAs
as important mediators for the modulation of the VSMC
phenotype by targeting transcription factors and the
cytoskeleton, which acts as molecular switches for
VSMC differentiation [10]. In these cells, the Mir143/
145 gene cluster plays a major role in regulating the
contractile phenotype and controling responses to vari-
ous types of injury [11-13].
The reduction of endothelial miRNAs by inactivation
of Dicer both in vitro [14] and in vivo using Cre-
recombinase under the regulation of tie2 promoter/en-
hancer or tamoxifen inducible expressed Cre-recombinase
(Cre-ERT2) under the regulation of vascular endothelial
cadherin promoter was shown to reduce postnatal angio-
genic response to a variety of stimuli, including exogenous
VEGF, tumors, limb ischemia, and wound healing [15]. In
vitro studies demonstrated the presence of miRNAs in
endothelial cells [16,17] and silencing of Dicer using short
interfering (si)RNA in human endothelial cells resulted in
impaired capillary-like structures and reduced cell growth
[18-21]. The angiogenic properties of members of the mir
1792 cluster have been extensively studied [15,22,23].
Also, miR-92a, miR-15a, miR-126 were identified to target
mRNAs corresponding to several proangiogenic proteins,
such as FGF2 and VEGF [22,24-28]. In addition, recent
studies reported the role of miR-99b, miR-181a, and miR-
181b in the differentiation of human embryonic stem cells
to vascular endothelial cells [29]. In the vascular endothe-
lium, recent findings have shown that miRNAs such as
mir-210 orchestrate the response to hypoxia [30,31] and
that down-regulation of Dicer under chronic hypoxia is an
adaptive mechanism that serves to maintain the cellular
hypoxic response through HIF-α and miRNA-dependent
mechanisms [29]. Functional deficiency of Dicer in
chronic hypoxia is relevant to both HIF-α isoforms and
hypoxia-responsive/HIF target genes. The regulation of
Prox1 by miR-181 further highlighted the contribution of
RNA interference in the induction of lymphatic endothe-
lium. Indeed, miR-181 is highly expressed in the blood
vasculature, but significantly reduced in lymphatic endo-
thelial cells, reciprocally to Prox1 expression [32].
However, whether Dicer could regulate angiogenesis,
especially during development when hypoxia is a major
stimulus remains largely unclear. There is still insuffi-
cient evidence for the involvement of RNA interference
during the early stages of vascular cell development, and
particularly in the control of endothelial arterial-,
venous-, and lymphatic- fate specification. Here, we
show that conditional inactivation of Dicer in mice ex-
pressing Cre recombinase under the control of the tie2
promoter causes no major alterations in EC fates and dif-
ferentiation but leads to unexpected functional and
morphologic alterations in the separation of blood and
lymphatic vasculature.
Methods
Mice
The experiments were performed in accordance with the
guidelines of the French Ministry of Agriculture. This
study conforms to the standards of INSERM (the French
National Institute of Health) in accordance with European
Union Council Directives (86/609/EEC). All experiments
were performed blindly, meaning that the experimenter
was blind to the mouse genotype.
Mice were backcrossed to the C57BL/6 J background
for more than 10 generations.
tie2-Cre:dicerfl/+ (dicerΔEC/+) males were crossed with
dicerfl/fl females to generate embryos. The day of vaginal
plug observation was considered as E0.5. Genotyping
was performed on embryonic fragments using the fol-
lowing PCR primer pairs: Cre-R 5-AACAGCATTGCT
GTCACTTGGTCG-3 and Cre-F 5-ATTACCGGTCG
ATGCAACGAGTGA-3 (product size: 350-bp); DicerF1
5-CCTGACAGTGACGGTCCAAAG-3 and DicerR1
5-CATGACTCTTCAACTCAAACT-3 (product sizes:
420-bp dicerΔ allele and 351-bp wild-type dicer allele).
ROSA26-R embryos were genotyped by PCR using three
oligonucleotides: ROSA-1 5-AAAGTCGCTCTGAGTT
GTTAT-3, ROSA-2 5-GCGAAGAGTTTGTCCTCAA
CC-3 and ROSA-3 5-GGAGCGGGAGAAATGGATA
TG-3. Dicerfl/+ and dicerfl/fl are thereafter designated as
wild type (WT) embryos, dicerΔEC/+ and dicerΔEC/ΔEC
called heterozygous and mutant embryos respectively.
Efficient Cre recombinase-mediated excision of the
floxed dicer allele was detected on PECAM+ endothelial
cells from dicerΔEC/+ and dicerΔEC/ΔEC embryos. Briefly,
mouse tissues were incubated in 5 mL Dulbecco modified
Eagle medium containing 200 U/mL collagenase I (Invi-
trogen) for 45 minutes at 37°C with occasional shaking
followed by filtering through a 40-μm nylon mesh. The
cells were then centrifuged for 5 minutes at 4°C, resus-
pended in Buffer 1 (0.1% bovine serum albumin, 2 mM
EDTA pH 7.4 in phosphate-buffered saline) and incubated
with anti rat immunoglobulin G-coated magnetic beads
(Invitrogen) precoupled with rat antimouse platelet/
endothelial cell adhesion molecule-1 (PECAM-1; MEC13.3,
BD Pharmingen) for 30 minutes at 4°C. Beads were sepa-
rated using a magnetic particle concentrator (Dynal MPC-
S, Invitrogen). The beads were washed 5× with Buffer 1
and centrifuged for 5 minutes at 3400 g, and the super-
natant removed as previously described [33]. PCR analysis
was performed using primers DicerF1 and DicerDel 5-
CCTGAGCAAGGCAAGTCATTC-3. The deletion allele
produced a 471-bp PCR product whereas a wild-type al-
lele resulted in a 1,300-bp product.
X-Gal staining
Embryos were harvested at different stages and fixed in
4% formaldehyde for 10 min at RT, rinsed twice in 1X
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phosphate-buffered saline, and incubated overnight at
37°C in buffer containing PBS 1X, 0.1 M sodium phos-
phate (pH 7.3), 2 mM magnesium chloride, 0.02% NP-40,
0.01% sodium deoxycholate, 5 mM potassium ferricyan-
ide, 5 mM potassium ferrocyanide, and 1 mg/ml X-gal
(5-bromo-4-chloro-3-indoyl β-D-galactopyranoside).
Histological analysis
Embryos were harvested, fixed in 4% paraformaldehyde
overnight and embedded in paraffin. Histologic speci-
men of mouse tissue was stained with hematoxylin and
eosin.
Immunohistochemistry
Paraffin-embedded sections were deparaffinized, perme-
abilized, and incubated with goat polyclonal anti-VEGFR-
3 (1:100, R&D Systems) or anti VEGFR-2 (1:100, R&D
Systems) followed by biotin-streptavidin-HRP amplifica-
tion using the Vectastain-ABC kit (Vector Lab), and post-
stained with eosin.
For whole-mount staining, tissues were fixed overnight
in 4% PFA and blocked overnight in blocking buffer
(PBS, 5% goat serum, 0.3% Triton X-100, and 0.2%
BSA). Tissues were incubated overnight at 4°C with bio-
tinylated antimouse LYVE-1 (1:100, R&D Systems) or
PECAM-1 (1:100, BD Biosciences) in blocking buffer
followed by biotin-streptavidin-HRP amplification using
the Vectastain-ABC kit.
Results
To bypass the early embryonic lethality of dicer-null
mice [2], we developed a new Cre-loxP-mediated condi-
tional deletion of dicer in tie2-expressing cells in order
to investigate its role in vascular development. To this
end, we crossed dicer-floxed mice (dicerfl/fl) [4] with
tie2-Cre transgenic mice [4,34]. The resulting heterozy-
gous double transgenic mice (dicerΔEC/+) were viable. In-
tercrosses of dicerΔEC/+ male with dicerfl/fl females
yielded no dicerΔEC/ΔEC pups out of 293 viable offspring
at birth (see Table 1). These data suggested that mice
bearing dicer gene deficiency in tie2-expressing cells do
not survive embryogenesis. To determine when the
dicerΔEC/ΔEC mice died, embryos were examined from
E10.5 to birth. Embryos were removed and embryonic
DNA was analyzed for homo- or heterogeneity of the
floxed allele. This genotype was then correlated with the
viability of the embryo. Mendelian ratios were observed
from E10.5 to E13.5 (see Table 1). Mutant embryos from
E10.5 to E11.5 were macroscopically indistinguishable
from the control littermates. At later stages, E12.5 on-
wards, macroscopic examination revealed the presence
of hemorrhages and edema in mutant embryos that in-
creased in size and number with age (Figure 1A). Geno-
typing PECAM+ endothelial cells showed efficient dicer
inactivation in E13.5 dicerΔEC/ΔEC embryos compared to
E13.5 dicerΔEC/+ embryos here used as controls (Figure 1B).
Recombination was also monitored in tie2-expressing
cells using the ROSA26 (R26) reporter line [35]. We
then crossed the dicerΔEC/+ males with homozygous
dicerfl/fl:R26/R26 females to generate dicerΔEC/+:R26/+
(heterozygous, here as a control) and dicerΔEC/ΔEC:R26/+
(mutant) triple transgenic embryos. As indicated by
whole-mount X-Gal staining, the recombination was ef-
ficient in blood endothelial cells thereby allowing us to
compare the pattern of the vascular network in mutant
and control embryos using LacZ staining (Figure 2). Be-
tween E10.5 and E12.5, dicerΔEC/ΔEC embryos did not
display obvious blood vascular defects: avascular regions
were not observed in control embryos. X-Gal-stained
blood vessels formed properly and vascular density was
comparable in both control and mutant embryos
(Figure 2). Whole-mount staining using an anti-PECAM
antibody confirmed these observations as reported in
Figure 3A showing that vascular patterning of blood ves-
sels was comparable to controls in E11.5 dicerΔEC/ΔEC em-
bryos. In order to study the development of the blood
vessel network in greater details, branchpoints of the cra-
nial vascular network (internal carotid artery) were
quantified on E11.5 embryos. The number of branch-
points in the internal carotid artery was not statistically
different in dicerΔEC/ΔEC embryos compared to WT em-
bryos (Figure 3B).
Between E12.5 and E14.5, extensive edema gradually
progressed on the back of the embryos and was some-
times filled with blood cells in dicerΔEC/ΔEC embryos
which were all dead at E14.5 (Figure 1 and Table 1). This
also phenocopies the effects observed upon genetic dele-
tion of Prospero homeobox 1 (prox-1) [36], Src hom-
ology domain-containing leukocyte protein-76 (slp-76)
[37] or C-type lectin-like receptor 2 (clec-2) [38]. All
show impaired lymphatic vessel development and die in
utero with severe edema and hemorrhages. To establish
whether dicerΔEC/ΔEC embryos also present defects in
Table 1 Genotype analysis in percentages of live embryos
resulting from the cross of a dicerΔ/+ male with a dicerfl/fl
female
WT dicerΔEC/+ dicerΔEC/ΔEC
Expected ratios 50% 25% 25%
E10.5 n = 119 47.1% 28.5% 24.4%
E11.5 n = 49 49% 30.8% 20.4%
E12.5 n = 31 37.5% 38.7% 23.8%
E13.5 n = 90 36.6% 26.7% 36.7%
E14.5 n = 29 34.5% 23.8% 9.5%
E15.5 n = 4 50% 50% 0%
P14 n = 293 63.9% 36.1% 0%
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lymphatic vessels development, we examined transverse
sections of mutant embryos. At E13.5, we never ob-
served any disruption of the main blood vessels i.e. the
thoracic aorta or the cardinal vein in dicerΔEC/ΔEC em-
bryos (Additional file 1: Figure S1 and Figure 4). The
lymph sacs, the first lymphatic structure that emerges
from the cardinal vein [39] during development, also ap-
peared normal (Additional file 2: Figure S2). At E13.5
however, in contrast to control embryos, these lymph
sacs were filled with blood cells in dicerΔEC/ΔEC embryos
(Figure 4A). The lymphatic identity of the blood-filled
structures was confirmed by the expression of lymphatic
markers VEGFR-3 (Figure 4A) and PROX-1 (Additional
file 3: Figure S3). Moreover, LYVE-1 whole-mount
immunostaining evidenced a complete overlap between
blood-filled structures and the lymphatic vasculature in
E14.5 mutant embryos (Figure 4B), confirming the
blood-filled lymphatics phenotype.
Altogether, these data indicate that dicer inactivation
in tie2 expressing cells leads to embryonic lethality at
E14.5, and to a failure in the separation of lymphatic
vessels during embryonic angiogenesis.
Discussion
Here, using Cre/loxP-mediated inactivation of dicer in
tie2-expressing cells, we demonstrate for the first time
that embryonic venous-lymphatic separation is submit-
ted to epigenetic control by RNA interference. Previous
Figure 1 Conditional deletion of dicer gene leads to hemorrhage and edema. A) Whole-mount view of WT and dicerΔEC/ΔEC embryos from
E12.5 to E14.5. Hemorrhagic regions and edema are indicated (arrows). Scale Bar: 500 μm. B) PCR genotyping analysis of PECAM+ endothelial cells
from E13.5 dicerΔEC/+ and dicerΔEC/ΔEC embryos. Detection of Cre and dicer fragments (floxed, excised and WT) are presented.
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studies using a similar approach of conditional dicer de-
ficiency using tie2-Cre and ve-cadherin-CRE-ERT2 have
reported reduced postnatal angiogenesis but no develop-
mental defects [15]. The likely explanation for this
discrepancy probably relies on the use of a different
dicer-floxed mouse leading to the presence of residual
Dicer protein levels in tie2-Cre:dicerfl/fl endothelial cells,
reflecting an incomplete excision of the dicer allele [15].
Thus, these mice were hypomorphic for dicer in ECs
and tie2-Cre:dicerfl/fl newborn litters were overtly nor-
mal and indistinguishable from their littermate controls.
In contrast, in the present study, efficient dicer inactiva-
tion was evidenced in PECAM+ endothelial cells which
showed complete excision of dicer in dicerΔEC/ΔEC em-
bryos. The present study thus shows that dicer gene de-
letion in Tie2 expressing cells leads to embryonic
lethality at E14.5. Mutant embryos, which display hem-
orrhages and edema, showed blood-filled lymphatics
without evident angiogenesis defects at early stages.
We here used the well-documented tie2-Cre trans-
genic mice that express Cre in a pan-endothelial fashion
for vascular endothelial targeting [34]. With the Rosa26
reporter line, we showed recombination in lymphatic
vessels (Additional file 4: Figure S4). Using the same
tie2-Cre ROSA26 strain, Srinivasan et al. demonstrates
that at E11.5, Prox1+ endothelial cells in the anterior
cardinal vein and those budding from it were lacZ+.
Similarly, all E13.5 and E14.5 Prox1+ endothelial cells in
the lymph sacs were lacZ+[40]. Nevertheless, it should
be noted that it has also been reported that tie2-Cre
transgenic mice express Cre in blood island progenitors
[41,42]. Recent studies have highlighted the role of
hematopoietic cells during the process of separation
between the venous and the lymphatic vasculature. It
has been shown that podoplanin, a transmembrane pro-
tein expressed on lymphatic endothelial cells, engages
the platelet receptor CLEC-2 leading to Syk-Slp-76-
dependent platelet activation [43]. Deletion of these
genes leads to aberrant vascular connection between
blood and lymphatic vessels. Similar lymphovenous con-
nections were also observed in mice deficient for the
homeodomain transcription factor Meis1 (myeloid eco-
tropic viral integration site 1) which completely lack
megakaryocyte/platelets and for the transcription factor
Figure 2 Mutant embryos do not display vascular defects. A-C) Whole-mount view of X-Gal staining of dicerΔEC/+:R26/+ embryos and
dicerΔEC/ΔEC:R26/+ embryos from E10.5 to E12.5. Scale Bar: 500 μm. The vascular network is identical in mutant and control embryos (n = 3 for
each condition).
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Runx1 which lack hematopoietic stem cells [40,44]. It
should also be noted that runx1 mutant embryos, which
lack platelets, present hemorrhages in the brain [45],
which could also be observed in some dicerΔEC/ΔEC em-
bryos. Because platelets also act to maintain vascular in-
tegrity and as the brain and lungs are more susceptible
to haemorrhage in a mouse model of acute severe
thrombocytopenia induced by platelet depletion [46],
these hemorrhages most likely occur secondary to the
lack of platelets. These data showed that platelets are re-
quired during embryonic lymphangiogenesis for the sep-
aration of the nascent lymphatic vasculature from blood
vessels [47,48]. However, recent studies by Yang et al.
[49] and Hägerling et al. [50] have disproved a direct
involment of platelets in the emergence of the first jugu-
lar lymph sacs. Podoplanin expression only starts after
lymphatic endothelial cells leave the cardinal vein sug-
gesting that platelets have a role restricted to the region
where lymphatics and blood vessels coalesce, in the lym-
phovenous valves. Nevertheless, the presence of blood
cells in lymphatic vessels may also indicate an incom-
plete separation of blood and lymph vessel, but could
also result from de novo connections of previously sepa-
rated blood and lymph vessels. Recently, Hess et al.
proved that platelets interact with lymphatic endothelium
valves specifically at the thoracic duct-subclavian vein
junction [51]. Blood-filled lymphatics arise due to backfill-
ing of the lymphatic vascular network from this site either
due to a lymphovenous valve defect or due to a platelet
aggregation defect. We therefore looked at the thoracic
duct-subclavian vein junction and we determined that the
lymphovenous valves appears normal (Additional file 5:
Figure S5) suggesting a defect in platelet aggregation.
We therefore sought to decipher whether perturbing
dicer expression in megakaryocytes could also reproduce
a blood-filled lymphatic phenotype during development
by generating pf4-cre:dicerfl/fl mice. Pf4-cre express Cre-
recombinase in the megakaryocytic lineage as previously
shown [52] and are a useful tool to study megakaryopoi-
esis, and platelet function. These mice were born at nor-
mal mendelian ratio and the separation of the lymphatic
vasculature from the blood vessels was not disrupted
during development (Additional file 6: Figure S6 and
Table 2). Recombination was observed in liver megakar-
yocytes before venous-lymphatic separation, as soon as
E11.5 (data not shown) and persisted at E16.5 (Additional
file 4: Figure S4B). However, the pf4-Cre transgene is also
partially expressed in other hematopoietic lineages and
the recombination pattern during early embryogenesis is
not clear [53]. A megakaryocyte specific promoter that
Figure 3 Blood vessel patterning normally occurs in mutant embryos. A) Whole-mount immunohistochemical staining by anti-PECAM-1
antibody on E11.5 embryos. Scale Bar: 500 μm. B) Branchpoints quantification (means ± SEM) of the internal carotid artery (ica) on E11.5 embryos.
The number of branchpoints is similar in WT and dicerΔEC/ΔEC embryos (ica; dots represent arterial branchpoints; e, eye; v, veins). (WT n = 10,
dicerΔEC/ΔEC n = 5).
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could allow earlier deletion might be useful but does not
exist.
Also, cells from the myeloid lineage play a critical role
in this separation. Abnormal infiltration of a specific
monocyte population in syk-deficient mice leads to lymph-
atic hyperplasia, vessel dilation and blood-lymphatic
shunts [54]. Tie2 is expressed in the early yolk sac meso-
derm suggesting that recombination may occur in
hematopoietic cells [55]. The use of a more endothelial
specific strains such as ve-cadherin-CRE-ERT2 [56] or
pdgfb-CRE-ERT2 [57] would also be very useful for under-
standing the specific role of Dicer in the endothelium.
Figure 4 Mutant embryos present blood-filled lymphatics. A) Histological analysis of E13.5 WT and dicerΔEC/ΔEC embryos. dicerΔEC/ΔEC embryos
display blood-filled structures contrary to WT embryos as revealed after hematoxylin/eosin staining (HE) (upper panel). Immunostaining with the
lymphatic marker VEGFR-3 confirmed the lymphatic identity of the blood filled structures (lower panel). Cv: cardinal vein, ls: lymph sac. Scale bar:
50 μm. (n = 2 for each condition). B) Whole-mount view of a E14.5 dicerΔEC/ΔEC embryo after dissection (Left panel). Hemorrhages are indicated by
Δarrows. Immunohistochemical staining by anti-LYVE-1 antibody on the same mutant embryo (Right panel). Scale Bar: 500 μm. Higher magnification
of the dicerΔEC/ΔEC embryo after dissection and after LYVE-1 staining respectively (Lower panel). There is a complete overlap between hemorrhages and
LYVE-1 staining indicating blood-filled lymphatics in the dicerΔEC/ΔEC embryo. (n = 2).
Table 2 Genotype analysis in percentages of live pups
resulting from the cross of a pf4-cre:dicerΔ/+ male with a
dicerfl/fl female
WT pf4-cre:dicerΔ/+ pf4-cre: dicerΔ/Δ
Expected ratios 50% 25% 25%
P14 n = 40 45% 30% 25%
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However, the CRE activation is tamoxifen-dependent
making these models more suitable for postnatal angio-
genesis as recombination at a precise embryonic time
point might be somewhat difficult to achieve in a very re-
producible manner.
MicroRNAs are involved in many aspects of physio-
logical and malignant hematopoiesis but surprisingly, no
existing studies have focused on the role of dicer during
hematopoietic development. However, dicer invalidation
in adult has been described. Buza-Vidas et al. showed
that dicer is required during erythroid lineage differenti-
ation [58]. It was also suggested that Dicer is involved in
the regulation of the hematopoietic stem cell niche as
well as the regulation of hematopoietic stem cell number
[59,60]. The blood filled phenotype that we observed
could result from either a defect of hematopoiesis or a
volume expansion of the blood stream indirectly affect-
ing lymphatic development. We therefore believe that
further experiments, outside of the scope of the present
manuscript, will be needed to determine precisely
whether hematopoiesis is modulated in dicerΔEC/ΔEC em-
bryos and to fully decipher the cellular and molecular
mechanisms responsible for the blood-filled lymphatic
phenotype in these mice.
Conclusion
Taken together, these results show a new role for RNA
interference in epigenetic control of embryonic venous-
lymphatic separation and provide a knowledge base for
further investigations to validate functional roles for
microRNAs.
Additional files
Additional file 1: Figure 1. Histological analysis of E13.5 thoracic aorta
in WT and dicerΔEC/ΔEC embryos. Immunostaining with VEGFR-2 confirmed
a normal patterning of the thoracic aorta of dicerΔEC/ΔEC embryos. Scale
Bar: 2 μm. (n = 3).
Additional file 2: Figure 2. Mutant embryos do not present lymph sacs
defect. Whole-mount view of E12.5 WT and dicerΔEC/ΔEC embryos after
LYVE-1 staining. The mutant embryo do not show a lymph sac defect.
(n = 3 for each condition).
Additional file 3: Figure 3. Prox1 expression on transversal sections of
E13.5 WT and dicerΔEC/ΔEC embryos (n = 2 for each condition). Prox1
expression is maintained in lymphatics vessels in mutant embryos (upper
panel), and the number of Prox1 expressing cells is similar in WT and
dicerΔEC/ΔEC embryos (lower panel).
Additional file 4: Figure 4. Whole-mount view of X-Gal staining of
dicerΔEC/ΔEC:R26/+ embryos at E13.5. Mutant embryo present recombination
in lymphatic vessels (indicated by arrows). (n = 5).
Additional file 5: Figure 5. Histological analysis of E13.5 lymphovenous
valves in WT and dicerΔEC/ΔEC embryos (indicated by arrows).
Immunostaining with VEGFR-3 showed a normal patterning and morph-
ology of the lymphovenous valves of dicerΔEC/ΔEC embryos. Scale Bar: 2
μm. (n = 2 for each condition).
Additional file 6: Figure 6. Conditional deletion of dicer in
megakaryocytes does not lead to embryonic lethality. A) Whole-mount
view of WT and pf4-cre:dicerΔ/Δ embryos at E16.5. Mutant embryos do
not present any obvious phenotype. B) Whole-mount view of X-Gal
staining of a pf4-cre:dicerΔ/Δ liver at E16.5 (Left panel). Histological analysis
of the same E16.5 liver (Right panel). Recombination occurs in typical
large megakaryocytes in the liver. (n = 3).
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